Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay
Sponsor: Invivoscribe, Inc.
Summary
This protocol describes the pivotal accuracy study for the IdentiClone Dx TRG Assay. The intent of the accuracy study is to demonstrate agreement between the results of the IC TRG Dx Assay and a predicate devise or assay on retrospective and residual de-identified DNA extracted from FFPE (Formalin Fixed Paraffin Embedded) samples from individuals with suspected T-Cell Lymphoproliferations. The predicate device will be the LymphoTrack Dx TRG (FR1/FR2/FR3) Assays - MiSeq (LT Dx TRG-CE-IVD), which is a CE-IVD assay with a similar intended use as the IC TRG Assay on the same sample type.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
250
Start Date
2025-06-02
Completion Date
2025-12-06
Last Updated
2025-03-14
Healthy Volunteers
No
Conditions
Interventions
IdentiClone Dx TRG Assay
The IdentiClone Dx TRG Assay ("Assay") is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers.
Locations (3)
Invivoscribe, Inc.
San Diego, California, United States
LabPMM GmbH
Hallbergmoos, Germany
LabPMM GK
Kawasaki-shi, Kanagawa, Japan